| Literature DB >> 33732350 |
Peng Wang1,2, Na Xue2,3, Chunyan Zhang4, Shimin Shan1,2, Zhongmin Jiang2,5, Wenhan Wu2,6, Xiaozhi Liu2,3.
Abstract
Surgery for patients with complicated liver cancer often results in a long exposure to anesthesia with an increase in side effects. Continued long-term exposure to isoflurane may promote liver cancer progression. Small ubiquitin-like modifier (SUMO) 2 and 3, also known as SUMO2/3, conjugates to substrate proteins when cells undergo acute stress. However, whether or not SUMO2/3 is involved in isoflurane-mediated liver cancer progression is unknown. In the present study, hepatocellular carcinoma (HCC) cells were exposed to 2% isoflurane for 12 h, followed by 36 h of drug withdrawal, and the formation of SUMO2/3 conjugates and cancer behavioral characteristics were studied. The results demonstrated that the formation of SUMO2/3 conjugates was significantly increased following HCC cells being exposed to isoflurane for 0.5 h, and continued to increase for 48 h, even after the drug had been withdrawn. Furthermore, isoflurane-exposed HCC cells exhibited increased proliferation and invasion activity during the subsequent observation period. SUMO specific protease 3 (SENP3), which inhibits the binding of SUMO2/3 to its target proteins, was overexpressed and it was discovered that isoflurane-induced SUMOylation was significantly inhibited, and accordingly, the proliferation and invasion abilities of HCC cells were decreased to a certain extent. These findings indicated that SUMO2/3 is involved in the progression of HCC cells, at least in the Hep3B cell line, induced by the anesthetic isoflurane, and that inhibition of SUMO2/3 may antagonize the response. These results provided a novel target for decreasing the adverse reactions occurring in patients with HCC during anesthesia, particularly those who are exposed to isoflurane for long periods of time. Copyright: © Wang et al.Entities:
Keywords: hepatocellular carcinoma; invasion; isoflurane; proliferation; small ubiquitin-like modifier
Year: 2021 PMID: 33732350 PMCID: PMC7905670 DOI: 10.3892/ol.2021.12535
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Information regarding all antibodies used in the present study.
| Antibody | SUMO2/3 | SENP3 | GFP | β-actin | IgG | IgY |
|---|---|---|---|---|---|---|
| Supplier | Abcam | Abcam | Abcam | Abcam | Santa Cruz Biotechnology, Inc. | Abcam |
| Catalog no. | ab3742 | ab124790 | ab13970 | ab8227 | sc-2357 | ab6877 |
| Dilution factor | 1:1,000 | 1:2,000 | 1:5,000 | 1:1,000 | 1:2,000 | 1:2,000 |
SENP3, SUMO specific protease 3; SUMO2/3, small ubiquitin-like modifier 2/3.
Figure 1.Isoflurane increases the production of SUMO2/3 conjugates in hepatocellular carcinoma cells. (A) The protein expression of SUMO2/3 conjugates was determined by Western blot analysis. (B) Bar graph from A. Data are presented as the means ± standard deviation (n=3); **P<0.01 or ***P<0.001, compared with the 0 h group. ∆P<0.05, compared with the 12 h group. SUMO2/3, small ubiquitin-like modifier 2/3.
Figure 2.Isoflurane exposure promotes the malignant progression of HCC cells. (A) The proliferation activity of HCC cells was evaluated using a Cell Counting kit-8 assay. (B and C) The migratory ability of HCC cells was determined by a wound healing experiment (scale bar, 20 µm). (D and E) The invasive ability of HCC cells was determined by a Transwell experiment (scale bar, 20 µm). Data are presented as the mean ± standard deviation (n=8); *P<0.05, **P<0.01, compared with the control group. HCC, hepatocellular carcinoma.
Figure 3.SENP3 overexpression inhibits SUMO2/3 conjugate formation. (A) Protein expression was investigated by Western blot analysis. (B) Bar graph of data from A. Data are presented as the mean ± standard deviation (n=3); **P<0.01 or ***P<0.001, compared with the 0 h group. SENP3, SUMO specific protease 3; SUMO2/3, small ubiquitin-like modifier 2/3.
Figure 4.SENP3 overexpression antagonizes the malignant progression of HCC cells caused by isoflurane exposure. (A) Proliferation of HCC cells was determined by a Cell Counting kit-8 assay. (B and C) The migratory ability of HCC cells was determined using a wound healing assay (scale bar, 20 µm). (D and E) The invasive ability of HCC cells was determined by a Transwell experiment (scale bar, 20 µm). Data are presented as the mean ± SD (n=8); *P<0.05, **P<0.01, compared with the control group. ∆P<0.05, compared with the isoflurane exposure group. SENP3, SUMO specific protease 3; HCC, hepatocellular carcinoma.